Related Experiment Video

Updated: Aug 9, 2026

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

Recent advances in pharmacotherapy for cancer pain management

Lise K Lucas1, Arthur G Lipman

  • 1College of Pharmacy, University of Utah, Salt Lake City 84112, USA.

Cancer Practice
|May 25, 2002
PubMed
Abstract

Insights

Recent advances in cancer pain management include novel NSAIDs, fentanyl citrate, and adjuvant therapies for neuropathic pain. Ongoing research into NMDA receptor antagonists and bisphosphonates offers further improvements in pain relief for cancer patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Pain Management

Background:

  • Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs (NSAIDs) and transmucosal fentanyl citrate offer new pharmacologic options for cancer pain.
  • Adjuvant agents, including antidepressants and topical analgesics, are expanding the treatment spectrum for neuropathic pain.
  • Research continues on N-methyl-d-aspartate (NMDA) receptor antagonists for enhanced analgesia and combating opioid resistance.

Purpose of the Study:

  • To review recent advances in drug treatment options for cancer pain management.
  • To outline emerging strategies for effectively managing cancer pain.

Main Methods:

  • Literature review of recent advances in pharmacologic cancer pain management.
  • Synthesis of information on novel drug classes and therapeutic strategies.

Main Results:

  • Development of cyclooxygenase-2-selective NSAIDs and transmucosal fentanyl citrate.
  • Exploration of opioid agonist-antagonist combinations for balanced analgesia.
  • Expansion of adjuvant therapies for neuropathic pain, including antidepressants and topical agents.
  • Continued investigation into NMDA receptor antagonists and potent bisphosphonates for bone metastases.

Conclusions:

  • Emerging clinical research and professional experience are driving new cancer pain management strategies.
  • Implementation of these new strategies promises continued improvement in patient care.
  • Multidisciplinary approaches are essential for optimizing cancer pain management.

More Related Videos

Intracranial Pharmacotherapy and Pain Assays in Rodents02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers08:33

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...